Personally, I think if management had filed the 2nd quarter 10-Q, then Baudax would not be the only company in our trio filing an 8-K such as the one they filed today.
Money-hungry, small-cap biotechs, on the precipice of huge news, are prime targets for destruction, before their success can be realized. Moving us to the Expert Market (getting us out of the minefield), insulates us, to an extent, against the same fate Baudax has found itself in today.
What major fraud? Management has disclosed their financial constraints, although they may not yet have revealed their financial relief.
And the clinical trial data is verified in multiple peer-reviews.